@article{dda713ad2d8b4a41933dc112c43793e7,
title = "Differential vulnerability of thalamic nuclei in multiple sclerosis",
abstract = "Objectives: Investigating differential vulnerability of thalamic nuclei in multiple sclerosis (MS). Methods: In a secondary analysis of prospectively collected datasets, we pooled 136 patients with MS or clinically isolated syndrome and 71 healthy controls all scanned with conventional 3D-T1 and white-matter-nulled magnetization-prepared rapid gradient echo (WMn-MPRAGE) and tested for cognitive performance. T1-based thalamic segmentation was compared with the reference WMn-MPRAGE method. Volumes of thalamic nuclei were compared according to clinical phenotypes and cognitive profile. Results: T1- and WMn-MPRAGE provided comparable segmentations (0.84 ± 0.13 < volume-similarity-index < 0.95 ± 0.03). Medial and posterior thalamic groups were significantly more affected than anterior and lateral groups. Cognitive impairment related to volume loss of the anterior group. Conclusion: Thalamic nuclei closest to the third ventricle are more affected, with cognitive consequences.",
keywords = "MRI, differential vulnerability, segmentation, thalamic nuclei, thalamus, volumetry",
author = "Simon Blyau and Ismail Koubiyr and Manojkumar Saranathan and Pierrick Coup{\'e} and Mathilde Deloire and Julie Charr{\'e}-Morin and Aurore Saubusse and Bei Zhang and Brian Rutt and Vincent Dousset and Bruno Brochet and Aur{\'e}lie Ruet and Thomas Tourdias",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the TRAIL (Translational Research and Advanced Imaging Laboratory), laboratory of excellence (ANR-10-LABX-57). The SCICOG study was also supported by a grant from TEVA and ARSEP (Fondation pour l{\textquoteright}Aide {\`a} la Recherche sur la Scl{\'e}rose En Plaques). The SOCOG and MICROSEP studies were supported by a grant from the Bordeaux University Hospital. The PROCOG study was supported by a grant from Roche. The AUBACOG study was supported by a grant from Genzyme. This work has been performed with the help of the OFSEP (Observatoire Fran{\c c}ais de la Scl{\'e}rose En Plaques), which is supported by a grant provided by the French State and handled by the “Agence Nationale de la Recherche,” within the framework of the “Investments for the Future” program, under the reference no. ANR-10-COHO-002. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.B. has nothing to declare. I.K. received research grants from LabEx TRAIL (Translational Research and Advanced Imaging Laboratory) and ARSEP (Fondation pour l{\textquoteright}Aide {\`a} la Recherche sur la Scl{\'e}rose En Plaques). He received speakers{\textquoteright} honoraria from Celgene. M.S. has nothing to declare. P.C. has nothing to declare. M.D. has nothing to declare. J.C.-M. has nothing to declare. A.S. has nothing to declare. B.Z. is employee of Canon Medical. B.R. has nothing to declare. V.D. is member of the medical advisory board of Canon Medical. B.B. reports grants from the French Ministry of Health during the conduct of the study; personal fees and non-financial support from Biogen-Idec; grants from Merck-Serono; personal fees and non-financial support from Novartis; personal fees and non-financial support from Genzyme; grants, personal fees, and non-financial support from TEVA; and grants and non-financial support from Bayer, outside the submitted work. A.R. reports grants from TEVA, during the conduct of the study; personal fees and non-financial support from Novartis; personal fees and non-financial support from Biogen; grants, personal fees, and non-financial support from TEVA; grants and non-financial support from Roche; grants and non-financial support from Merck; grants and non-financial support from Genzyme; non-financial support from Medday; and grants from Bayer, outside the submitted work. T.T. received support from Roche and Canon Medical and recent grant supports from Idex Bordeaux, Bordeaux University Hospital, labEx BRAIN, and the national program for clinical research (PHRC). Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2023",
month = feb,
doi = "10.1177/13524585221114247",
language = "English (US)",
volume = "29",
pages = "295--300",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "2",
}